The miR-199a/Brm/EGR1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines

Scientific Reports

Volumn 5, Issue , 2015, Pages 8428-

  Kobayashi, Kazuyoshi ^a   Sakurai, Kouhei ^a   Hiramatsu, Hiroaki ^a   Inada, Ken Ichi ^b   Shiogama, Kazuya ^b   Nakamura, Shinya ^a   Suemasa, Fumiko ^a   Kobayashi, Kyosuke ^a   Imoto, Seiya ^a   Haraguchi, Takeshi ^a   Ito, Hiroaki ^a   Ishizaka, Aya ^a   Tsutsumi, Yutaka ^b   Iba, Hideo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAV1 PROTEIN, HUMAN; CAV2 PROTEIN, HUMAN; CAVEOLIN 1; CAVEOLIN 2; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN; HERMES ANTIGEN; MICRORNA; MIRN199 MICRORNA, HUMAN; SCATTER FACTOR RECEPTOR; SMARCA2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

BIOLOGICAL MODEL; CARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; HUMAN; METABOLISM; NON SMALL CELL LUNG CANCER; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD44; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CAVEOLIN 1; CAVEOLIN 2; CELL LINE, TUMOR; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-MET; TRANSCRIPTION FACTORS;

EID: 84923165673     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08428     Document Type: Article

References (60)

1. Wilson, B. G. & Roberts, C. W. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11, 481-92 (2011).
2. Ebert, M. S. & Sharp, P. A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515-24 (2012).
3. Iliopoulos, D., Hirsch, H. A. & Struhl, K. An epigenetic switch involving NFkappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139, 693-706 (2009).
4. Gurtan, A. M. & Sharp, P. A. The role of miRNAs in regulating gene expression networks. J Mol Biol 425, 3582-600 (2013).
5. Yaniv, M. Chromatin remodeling: from transcription to cancer. Cancer Genet 207, 352-357 (2014).
6. Mizutani, T. et al. Maintenance of integrated proviral gene expression requires Brm, a catalytic subunit of SWI/SNF complex. J Biol Chem 277, 15859-64 (2002).
7. Reisman, D. N. et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 21, 1196-207 (2002).
8. Kadam, S. & Emerson, B.M. Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes. Mol Cell 11, 377-89 (2003).
9. Mizutani, T. et al. Loss of the Brm-type SWI/SNF chromatin remodeling complex is a strong barrier to the Tat-independent transcriptional elongation of human immunodeficiency virus type 1 transcripts. J Virol 83, 11569-80 (2009).
10. Tando, T. et al. Requiem protein links RelB/p52 and the Brm-type SWI/SNF complex in a noncanonical NF-kappaB pathway. J Biol Chem 285, 21951-60 (2010).
11. Ishizaka, A. et al.Double plant homeodomain (PHD) finger proteins DPF3a and - 3b are required as transcriptional co-activators in SWI/SNF complex-dependent activation of NF-κB RelA/p50 heterodimer. J Biol Chem 287, 11924-33 (2012).
12. Yamamichi, N. et al. The Brm gene suppressed at the post-transcriptional level in various human cell lines is inducible by transient HDAC inhibitor treatment, which exhibits antioncogenic potential. Oncogene 24, 5471-81 (2005).
13. Reisman, D. N., Sciarrotta, J., Wang, W., Funkhouser, W. K. & Weissman, B. E. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 63, 560-6 (2003).
14. Yamamichi, N. et al. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 67, 10727-35 (2007).
15. Shen,H. et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res 68, 10154-62 (2008).
16. Yamamichi-Nishina, M. et al. SW13 cells can transition between two distinct subtypes by switching expression of BRG1 and Brm genes at the posttranscriptional level. J Biol Chem 278, 7422-30 (2003).
17. Sakurai, K. et al.MicroRNAs miR-199a-5p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. Cancer Res 71, 1680-9 (2011).
18. Gu, S. & Chan, W. Y. Flexible and Versatile as a Chameleon-Sophisticated Functions of microRNA-199a. Int J Mol Sci 13, 8449-66 (2012).
19. Baron, V., Adamson, E. D., Calogero, A., Ragona, G. & Mercola, D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 13, 115-24 (2006).
20. Pagel, J. I. & Deindl, E. Early growth response 1 - a transcription factor in the crossfire of signal transduction cascades. Indian J Biochem Biophys 48, 226-35 (2011).
21. Mariniello, B. et al. Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models. Endocr Relat Cancer 19, 527-39 (2012).
22. Hütz, K. et al. The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis 35, 942-50 (2014).
23. Shetty, R. S. et al. Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent. J Med Chem 54, 179-200 (2011).
24. Bilsland, A. E. et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 22, 370-80 (2003).
25. Lino Cardenas, C. L. et al. miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1. PLoS Genet 9, e1003291 (2013).
26. Henry, J. C. et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 403, 120-5 (2010).
27. Fornari, F. et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70, 5184-93 (2010).
28. Shatseva, T., Lee, D. Y., Deng, Z. & Yang, B. B. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci 124, 2826-36 (2011).
29. Karantza, V. Keratins in health and cancer: more than mere epithelial cell markers. Oncogene 30, 127-38 (2011).
30. Trask, D. K. et al. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc Natl Acad Sci U S A 87, 2319-23 (1990).
31. Ichimi, T. et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 125, 345-52 (2009).
32. Parton, R. G. & del Pozo, M. A. Caveolae as plasma membrane sensors, protectors and organizers. Nat Rev Mol Cell Biol 14, 98-112 (2013).
33. Zhang, J. et al. Identification of CD44 as a downstream target of noncanonical NF-κB pathway activated by human T-cell leukemia virus type 1-encoded Tax protein. Virology 413, 244-52 (2011).
34. Zhang, X. & Liu, Y. Suppression of HGF receptor gene expression by oxidative stress is mediated through the interplay between Sp1 and Egr-1. Am J Physiol Renal Physiol 284, F1216-25 (2003).
35. Joshi, B. et al. Phosphocaveolin-1 is a mechanotransducer that induces caveola biogenesis via Egr1 transcriptional regulation. J Cell Biol 199, 425-35 (2012).
36. Matsubara, D. et al. Lung cancer with loss of BRG1/BRM, shows epithelial mesenchymal transition phenotype and distinct histologic and genetic features. Cancer Sci 104, 266-73 (2013).
37. Mangan, S. & Alon, U. Structure and function of the feed-forward loop network motif. Proc Natl Acad Sci U S A 100, 11980-5 (2003).
38. Tsang, J., Zhu, J. & van Oudenaarden, A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell 26, 753-67 (2007).
39. Bourguignon, L. Y.,Wong, G., Earle, C., Krueger, K. & Spevak, C. C. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 285, 36721-35 (2010).
40. Singletary, K. & Ellington, A. Genistein suppresses proliferation and MET oncogene expression and induces EGR-1 tumor suppressor expression in immortalized human breast epithelial cells. Anticancer Res 26, 1039-48 (2006).
41. Ravid, D., Maor, S., Werner, H. & Liscovitch, M. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 24, 1338-47 (2005).
42. Kannan, A. et al. Caveolin-1 promotes gastric cancer progression by up-regulating epithelial to mesenchymal transition by crosstalk of signalling mechanisms under hypoxic condition. Eur J Cancer 50, 204-15 (2014).
43. Xu, Y., Stamenkovic, I. & Yu, Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 70, 2455-64 (2010).
44. Bourguignon, L. Y. Matrix hyaluronan-activated CD44 signaling promotes keratinocyte activities and improves abnormal epidermal functions. Am J Pathol 184, 1912-9 (2014).
45. Bolanos-Garcia, V. M. MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor. Mol Cell Biochem 276, 149-57 (2005).
46. Lloyd, P. G. Caveolin-1, antiapoptosis signaling, and anchorage-independent cell growth. Focus on "Caveolin-1 regulates Mcl-1 stability and anoikis in lung carcinoma cells". Am J Physiol Cell Physiol 302, C1282-3 (2012).
47. Kwon, H., Lee, J., Jeong, K., Jang, D. & Pak, Y. A novel actin cytoskeleton-dependent noncaveolar microdomain composed of homo-oligomeric caveolin-2 for activation of insulin signaling. Biochim Biophys Acta 1833, 2176-89 (2013).
48. Fujisaki, T. et al. CD44 stimulation induces integrin-mediated adhesion of colon cancer cell lines to endothelial cells by up-regulation of integrins and c-Met and activation of integrins. Cancer Res 59, 4427-34 (1999).
49. Elliott, V. A., Rychahou, P., Zaytseva, Y. Y. & Evers, B. M. Activation of c-Met and upregulation of CD44 expression are associated with the metastatic phenotype in the colorectal cancer liver metastasis model. PLoS One 9, e97432 (2014).
50. Singleton, P. A. et al. CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem 282, 30643-57 (2007).
51. Mora, R. et al. Caveolin-2 localizes to the golgi complex but redistributes to plasma membrane, caveolae, and rafts when co-expressed with caveolin-1. J Biol Chem 274, 25708-17 (1999).
52. Tatarelli, C., Linnenbach, A., Mimori, K. & Croce, C. M. Characterization of the human TESTIN gene localized in the FRA7G region at 7q31.2. Genomics 68, 1-12 (2000).
53. Hartman, Z. C. et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73, 3470-80 (2013).
54. Ito, T. et al. Brm transactivates the telomerase reverse transcriptase (TERT) gene and modulates the splicing patterns of its transcripts in concert with p54(nrb). Biochem J 411, 201-9 (2008).
55. Hoffman, G. R. et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Natl Acad Sci U S A 111, 3128-33 (2014).
56. Weinstein, I. B. & Joe, A. Oncogene addiction. Cancer Res 68, 3077-80 (2008).
57. Cheng, C. J. & Slack, F. J. The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J 18, 232-7 (2012).
58. Watanabe, H. et al. SWI/SNF complex is essential for NRSF-mediated suppression of neuronal genes in human nonsmall cell lung carcinoma cell lines. Oncogene 25, 470-9 (2006).
59. Haraguchi, T. et al. SiRNAs do not induce RNA-dependent transcriptional silencing of retrovirus in human cells. FEBS Lett 581, 4949-54 (2007).
60. Yamamichi, N. et al. Locked nucleic acid in situ hybridization analysis of miR-21 expression during colorectal cancer development. Clin Cancer Res 15, 4009-16 (2009).